26 December 2018 - - US-based healthcare holdings company Generex biotechnology Corp.'s (OTCQB: GNBT) Olaregen Therapeutix subsidiary has established a sales force in the wound care space and contracted with a Service-Disabled Veteran-Owned Small Business (SDVOSB) for distribution of Excellagen in the VA system through a network of veteran-owned distribution partners, the company said.

Olaregen provides a sales training programme for the sales team.

In addition to critical sales efforts, Olaregen is developing strategic relationships within the government Services Administration through a SDVOSB that maintains a network of veteran-owned marketing and distribution organisations that have preferred contractor status throughout the 21 Veteran Integrated Services Network regions.

Generex is a healthcare holdings company with offerings in a variety of services, diagnostics, medical devices, and pharmaceutical development.

The company's direct-to-patient services support its strategy of all-inclusive access to doctors, diagnostics, therapeutics, and additional health-related services to greatly improve the patient experience in receiving care.

On the provider side, Generex's management services remove administrative burdens in multiple provider settings, including private practice and hospital, allowing doctors to devote more time to patient care.

Revenue from the company's subsidiaries will support clinical advancement of its wholly owned therapeutic products with a focus on regenerative medicine, immunotherapy, and diabetes management.

Olaregen Therapeutix is a regenerative medicine company focused on the development, manufacturing and commercialization of products that fill unmet needs in the current wound care market.

The company aims to provide advanced healing solutions that substantially improve medical outcomes while lowering the overall cost of care. 

Olaregen's first product introduction, Excellagen (flowable dermal matrix) is a topically applied product for dermal wounds and other indications. 

Excellagen is a FDA 510K cleared device for a broad array of dermal wounds, including partial and full thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled/undermined wounds, surgical wounds (donor sites/ grafts, post-Mohs surgery, post-laser surgery, podiatric, wound dehiscence), trauma wounds (abrasions, lacerations, second-degree burns and skin tears) and draining wounds, enabling Olaregen to market Excellagen in multiple vertical markets.

Additionally, Excellagen can serve as an Enabling Delivery Platform for pluripotent stem cells, antimicrobial agents, small molecule drugs, DNA-Based Biologics, conditioned cell media and peptides.

Olaregen's initial focus will be in advanced wound care including diabetic foot ulcers, venous leg ulcers and pressure ulcers. Future products focusing on innovative therapies in bone and joint regeneration comprise the current pipeline.

The company's mission is to become a significant force in regenerative medicine and advance the science of healing.

This a Service-Disabled Veteran-Owned Small Business (SDVOSB) that specialises in the sale, marketing, and distribution of innovative medical products through a nationwide network of veteran owned distribution services.